Samuel S K Lam
Overview
Explore the profile of Samuel S K Lam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Lam S, Gao Y, Shore E, Anderson D, Hode T, et al.
Ann Surg Oncol
. 2024 Dec;
32(4):2786-2798.
PMID: 39739260
Background: This study aimed to evaluate the immunotherapeutic effect of irreversible electroporation (IRE) and IP-001 in pancreatic adenocarcinoma with metastasis. Methods: Orthotopic models of pancreatic adenocarcinoma with hepatic oligometastasis were...
2.
Li Y, Lam S, Wong C, Hode T, Anderson D, Martin R
Int J Hyperthermia
. 2024 Oct;
41(1):2413591.
PMID: 39389594
Background: Thermal ablation is reported to increase immunogenicity in tumor cells via expressing tumor antigens. IP-001, a synthesized molecule, is created by attaching galactose molecules to the free amino groups...
3.
Hoover A, More S, Liu K, West C, Valerio T, Furrer C, et al.
Acta Biomater
. 2023 Dec;
175:279-292.
PMID: 38160856
Mucosal vaccinations for respiratory pathogens provide effective protection as they stimulate localized cellular and humoral immunities at the site of infection. Currently, the major limitation of intranasal vaccination is using...
4.
Hoover A, Liu K, DeVette C, Krawic J, Medcalf A, West C, et al.
Clin Transl Med
. 2022 Jul;
12(7):e937.
PMID: 35808806
Background: Metastatic breast cancer poses great challenge in cancer treatment. N-dihydrogalactochitosan (GC) is a novel immunoadjuvant that stimulates systemic immune responses when administered intratumourally following local tumour ablation. A combination...
5.
Korbelik M, Hode T, Lam S, Chen W
Cells
. 2021 Mar;
10(3).
PMID: 33668932
Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly...
6.
Korbelik M, Banath J, Zhang W, Hode T, Lam S, Gallagher P, et al.
J Photochem Photobiol B
. 2020 Jan;
204:111780.
PMID: 31981988
Photothermal therapy (PTT) is recently clinically established cancer therapy that uses near-infrared light for thermal ablation of solid tumors. The biopolymer N-dihydrogalactochitosan (GC) was shown in multiple reports to act...
7.
Korbelik M, Banath J, Zhang W, Gallagher P, Hode T, Lam S, et al.
Int Immunopharmacol
. 2019 Jul;
75:105764.
PMID: 31352327
It is becoming apparent that to obtain robust and prolonged antitumor responses in cancer immunotherapy, appropriate adjunct agents promoting both tumor antigen delivery and immune rejection enhancement are critically required....
8.
El-Hussein A, Lam S, Raker J, Chen W, Hamblin M
J Biomed Mater Res A
. 2016 Dec;
105(4):963-972.
PMID: 28028922
Immunotherapy has become one of the fastest growing areas of cancer research. A promising in situ autologous cancer vaccine (inCVAX) uses a novel immune activator, N-dihydrogalactochitosan (GC), that possesses the...
9.
Lam S, Zhou F, Hode T, Nordquist R, Alleruzzo L, Raker J, et al.
Discov Med
. 2015 May;
19(105):293-301.
PMID: 25977192
Since the invention of Coley's toxin by William Coley in early 1900s, the path for cancer immunotherapy has been a convoluted one. Although still not considered standard of care, with...
10.
Zhou F, Li X, Naylor M, Hode T, Nordquist R, Alleruzzo L, et al.
Cancer Lett
. 2015 Jan;
359(2):169-77.
PMID: 25633839
A novel, promising potential cancer vaccine strategy was proposed to use a two-injection procedure for solid tumors to prompt the immune system to identify and systemically eliminate primary and metastatic...